Tumour targeting with l-enantiomeric oligonucleotide...

Details Tumour targeting with l-enantiomeric oligonucleotide... Tumour targeting with l-enantiomeric oligonucleotide...

C - Chemistry, Metallurgy

07

K

C07K 16/30 (2006.01) A61K 47/48 (2006.01) A61K 51/10 (2006.01) C07H 21/00 (2006.01)

Patent

CA 2157902

The present invention is directed to a non-radioactive targeting immunoreagent that comprises an immunoreactive group, one or more non-self-associating L-enantiomeric oligonucleotide sequences, and one or more linking groups, and to a radioactive targeting immunoreagent that comprises an L-enantiomeric oligonucleotide sequence that is complementary in sequence to and capable of hybridization with one or more fragments of a non-self-associating L-enantiomeric oligonucleotide sequence, one or more chelating agents, one or more linking groups, and one or more radionuclides. The present invention is also directed to pharmaceutical compositions comprising one or more of the above-described immunoreagents and a pharmaceutically acceptable carrier. The present invention is further directed to methods for treating and imaging disease sites in patients.

Affiliated with

Also associated with

Rating

Tumour targeting with l-enantiomeric oligonucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumour targeting with l-enantiomeric oligonucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumour targeting with l-enantiomeric oligonucleotide... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1695087